Results 11 to 20 of about 287,154 (333)
International Journal of Breast Cancer, 2012 Ever since the seminal work that was published by Perou et al., triple-negative breast cancer (TNBC) has become a common lexicon among clinicians who care for patients with breast cancer. Beside portending a poor outcome, TNBC is unique in that, unlike the hormone-positive and Her-2-positive cancer cells, it lacks target specific therapy.
Quyen D. Chu, Tari King, Thelma Hurd
doaj +8 more sources
Triple-negative breast cancer [PDF]
Wiener Medizinische Wochenschrift, 2010 Recent advances in biological characterization of breast cancer have eventually increased our understanding of underlying tumour biology. While for endocrine responsive and Her2-positive disease different molecular targeted therapies are available, up to now no specific targeted approach for triple-negative breast cancer has been developed.
Rupert, Bartsch +3 more
+13 more sources
Asian Pacific Journal of Cancer Prevention, 2014 Triple-negative breast cancers (TNBC), characterized by absence of the estrogen receptor (ER) and progesterone receptor (PR) and lack of overexpression of human epidermal growth factor receptor 2 (HER2), have a poor prognosis. To overcome therapy limitations of TNBC, various new approaches are needed.
Idil, Cetin, Mehmet, Topcul
+9 more sources
Male Triple-Negative Breast Cancer [PDF]
Cureus, 2021 Male breast cancer is a rarely encountered disease, when compared with female breast cancer, often detected in more advanced stage at the time of diagnosis, and associated with more lymph node metastasis rates, more estrogen receptors positivity, and less human epidermal growth factor receptor-2 expression (HER-2) rates.
Qavi, Qasif +4 more
openaire +2 more sources
Triple Negative Breast Cancer [PDF]
Klinicka onkologie, 2015 In the Czech Republic, around 6,500 women get breast cancer each year; out of this number, nearly 1,000 women are triple negative subtype. Triple negative breast cancer is characterized by lack of expression of α-estrogen, progesterone, and HER2 receptors.
J, Navrátil +5 more
openaire +2 more sources
Research progress of single-cell sequencing in neoadjuvant chemotherapy for triple-negative breast cancer [PDF]
Zhongguo aizheng zazhi, 2021 Triple-negative breast cancer is the most invasive and malignant type of breast cancer. At present, therapy for triple-negative breast cancer is the comprehensive treatment regimens based on chemotherapy, in which neoadjuvant chemotherapy plays an ...
HU Xi’e , YANG Zhenyu , XUE Jingyi , YANG Ping , PENG Shujia , YUAN Lijuan , BAO Guoqiang
doaj +1 more source
World Journal of Surgical Oncology, 2020 Background Metaplastic breast cancer remains poorly characterized given its rarity and heterogeneity. The majority of metaplastic breast cancers demonstrate a phenotype of triple-negative breast cancer; however, differences in clinical outcomes between ...
Evan Morgan +18 more
doaj +1 more source
miR-331-3p Suppresses Cell Proliferation in TNBC Cells by Downregulating NRP2
Technology in Cancer Research & Treatment, 2020 Purpose: Triple-negative breast cancer is characterized by fast progression with high possible for metastasis and poor survival. Dysfunction of microRNAs plays an important role in the initiation and progression of cancer.
Mingchuan Zhao PhD +5 more
doaj +1 more source
Impact of breast cancer subtypes on 3-year survival among adolescent and young adult women. [PDF]
, 2013 IntroductionYoung women have poorer survival after breast cancer than do older women. It is unclear whether this survival difference relates to the unique distribution of hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2)-defined ...
Clarke, Christina A +6 more
core +2 more sources
Technology in Cancer Research & Treatment, 2020 Background: Triple-negative breast cancer encompasses heterogeneous subtypes. Neoadjuvant chemotherapy is ineffective against some triple-negative breast cancers, while others show a favorable prognosis despite chemoresistance.
Koichi Kubouchi MD +3 more
doaj +1 more source